BioCentury | Apr 16, 2020
Deals

COVID R&D: Pharmas align behind crowdsourcing solution

Within under a month, a group that started as a mash-up of research heads has morphed into an organized and streamlined collaboration among top pharmaceutical company R&D leaders. Its simple name: COVID R&D. Its goal:...
BioCentury | Nov 16, 2019
Product Development

Major multinationals open, close, open R&D centers in China

After pulling back to reconsider their strategies, several pharmas are once again plunging into China’s life sciences innovation ecosystem, this time leaning more heavily on creation of innovation centers than R&D facilities. The changes reflect...
BC Innovations | Jul 19, 2019
Tools & Techniques

A mark up for RNA epigenetics

As a field, RNA epigenetics is still in its infancy, though picking up pace as researchers translate lab findings to drug development. Two papers straddling academia and industry provide a new quantitative method that can...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
BC Week In Review | Apr 15, 2013
Company News

Third Wave sales and marketing update

Third Wave began selling its Cleavase Enzyme Technology Toolbox to the worldwide research market. Cleavase uses a group of structure-specific cleaving agents to sequence and detect nucleic acid. The product also can measure gene expression...
BC Extra | Jun 9, 2012
Politics & Policy

EU's IMI details new research projects

The EU's Innovative Medicines Initiative announced details on its third wave of research projects that were launched in January with a total budget of EUR 215 million ($266.9 million) across five years. The projects include...
BC Week In Review | Apr 6, 2009
Company News

Exact Sciences management update

Exact Sciences Corp. (NASDAQ:EXAS), Marlborough, Mass.   Business: Diagnostic, Cancer   Hired: Kevin Conroy as president, CEO and a director, formerly president and CEO of Third Wave Technologies Inc. (now part of Hologic Inc. );...
BC Week In Review | Mar 23, 2009
Clinical News

16/18 genotyping HPV test regulatory update

FDA approved a PMA from Hologic for its Cervista HPV 16/18 test as an adjunct with the Cervista HPV HR test to detect HPV types 16 and 18 infection in women ages 30 and older...
BC Week In Review | Mar 23, 2009
Clinical News

14-type high-risk HPV test regulatory update

FDA approved a PMA from Hologic for its Cervista HPV HR test to detect 14 high-risk types of human papillomavirus (HPV) infection in women ages 30 and older and to screen patients whose Pap smears...
Items per page:
1 - 10 of 200
BioCentury | Apr 16, 2020
Deals

COVID R&D: Pharmas align behind crowdsourcing solution

Within under a month, a group that started as a mash-up of research heads has morphed into an organized and streamlined collaboration among top pharmaceutical company R&D leaders. Its simple name: COVID R&D. Its goal:...
BioCentury | Nov 16, 2019
Product Development

Major multinationals open, close, open R&D centers in China

After pulling back to reconsider their strategies, several pharmas are once again plunging into China’s life sciences innovation ecosystem, this time leaning more heavily on creation of innovation centers than R&D facilities. The changes reflect...
BC Innovations | Jul 19, 2019
Tools & Techniques

A mark up for RNA epigenetics

As a field, RNA epigenetics is still in its infancy, though picking up pace as researchers translate lab findings to drug development. Two papers straddling academia and industry provide a new quantitative method that can...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
BC Week In Review | Apr 15, 2013
Company News

Third Wave sales and marketing update

Third Wave began selling its Cleavase Enzyme Technology Toolbox to the worldwide research market. Cleavase uses a group of structure-specific cleaving agents to sequence and detect nucleic acid. The product also can measure gene expression...
BC Extra | Jun 9, 2012
Politics & Policy

EU's IMI details new research projects

The EU's Innovative Medicines Initiative announced details on its third wave of research projects that were launched in January with a total budget of EUR 215 million ($266.9 million) across five years. The projects include...
BC Week In Review | Apr 6, 2009
Company News

Exact Sciences management update

Exact Sciences Corp. (NASDAQ:EXAS), Marlborough, Mass.   Business: Diagnostic, Cancer   Hired: Kevin Conroy as president, CEO and a director, formerly president and CEO of Third Wave Technologies Inc. (now part of Hologic Inc. );...
BC Week In Review | Mar 23, 2009
Clinical News

16/18 genotyping HPV test regulatory update

FDA approved a PMA from Hologic for its Cervista HPV 16/18 test as an adjunct with the Cervista HPV HR test to detect HPV types 16 and 18 infection in women ages 30 and older...
BC Week In Review | Mar 23, 2009
Clinical News

14-type high-risk HPV test regulatory update

FDA approved a PMA from Hologic for its Cervista HPV HR test to detect 14 high-risk types of human papillomavirus (HPV) infection in women ages 30 and older and to screen patients whose Pap smears...
Items per page:
1 - 10 of 200